In Vivo Antibacterial Activity of Acetazolamide
Copyright © 2021 American Society for Microbiology..
Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two in vivo VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 65(2021), 4 vom: 18. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abutaleb, Nader S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.06.2021 Date Revised 19.09.2021 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01715-20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320572579 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320572579 | ||
| 003 | DE-627 | ||
| 005 | 20231225173852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01715-20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320572579 | ||
| 035 | |a (NLM)33495225 | ||
| 035 | |a (PII)e01715-20 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abutaleb, Nader S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Vivo Antibacterial Activity of Acetazolamide |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2021 | ||
| 500 | |a Date Revised 19.09.2021 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American Society for Microbiology. | ||
| 520 | |a Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two in vivo VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a VRE bloodstream infections | |
| 650 | 4 | |a VRE decolonization | |
| 650 | 4 | |a acetazolamide | |
| 650 | 4 | |a carbonic anhydrase inhibitors | |
| 650 | 4 | |a vancomycin-resistant enterococci (VRE) | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Linezolid |2 NLM | |
| 650 | 7 | |a ISQ9I6J12J |2 NLM | |
| 650 | 7 | |a Acetazolamide |2 NLM | |
| 650 | 7 | |a O3FX965V0I |2 NLM | |
| 700 | 1 | |a Elkashif, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Flaherty, Daniel P |e verfasserin |4 aut | |
| 700 | 1 | |a Seleem, Mohamed N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 65(2021), 4 vom: 18. März |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2021 |g number:4 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01715-20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2021 |e 4 |b 18 |c 03 | ||